DELTASOLONE TABLET 5 mg

Land: Singapore

Taal: Engels

Bron: HSA (Health Sciences Authority)

Werkstoffen:

PREDNISOLONE

Beschikbaar vanaf:

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

ATC-code:

H02AB06

Dosering:

5 mg

farmaceutische vorm:

TABLET

Samenstelling:

PREDNISOLONE 5 mg

Toedieningsweg:

ORAL

Prescription-type:

Prescription Only

Geproduceerd door:

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Autorisatie-status:

ACTIVE

Autorisatie datum:

1990-04-17

Productkenmerken

TL621B-R6
Revision Date: 02/09/2022
Visual disturbance
Visual disturbance may be reported with systemic and topical
corticosteroid use. If a patient
presents with symptoms such as blurred vision or other visual
disturbances, the patient should be
considered for referral to an ophthalmologist for evaluation of
possible causes which may include cataract,
glaucoma or rare diseases such as central serous chorioretinopathy
(CSCR) which have been reported after
use of systemic and topical corticosteroids.
USE IN PREGNANCY AND LACTATION:
Since adequate human reproduction studies have not been done with
corticosteroids, use of these
drugs in pregnancy or in women of childbearing potential requires that
the anticipated benefits be
weighed against the possible hazards to the mother and embryo or
fetus. Infants born of mothers who
have received substantial doses of corticosteroids during pregnancy
should be carefully observed for
signs of hypoadrenalism. Corticosteroids appear in breast milk and
could suppress growth, interfere with
endogenous corticosteroids production, or cause other unwanted
effects. Mothers taking pharmacologic
doses of corticosteroids should be advised not to nurse.
DOSAGE:
Oral administration.
It is usually given in a dose range of 5 to 60mg daily, in divided
doses or as a single daily dose at 8am or
as a double dose on alternate days.
In long term therapy, dosage should be maintained at not more than
about 7mg daily whenever possible
as side effects inevitably occur with higher dosage.
DRUG INTERACTIONS:
Phenytoin, phenobarbital, ephedrine and rifampicin may enhance the
metabolism of corticosteroids resulting
in decreased blood levels and lessened physiologic activity, thus
requiring adjustment in corticosteroid
dosage. Drugs such as barbiturates which induce hepatic microsomal
drug metabolizing enzyme
activity may enhance metabolism of Prednisolone and require the dosage
of Deltasolone to be adjusted.
Co-treatment with CYP3A inhibitors, including cobicistat-containing
products, is expected to incre